AlphaCrest Capital Management’s Emergent Biosolutions EBS Stock Holding History

AlphaCrest Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-33,648	Closed	-$706K	–	347
2022 Q3	$706K	Buy	33,648 +22,807	+210%	+$635K	0.04%	811
2022 Q2	$337K	Sell	10,841 -25,047	-70%	-$855K	0.02%	1079
2022 Q1	$1.47M	Buy	+35,888	New	+$1.58M	0.08%	369
2021 Q4	–	Sell	-4,563	Closed	-$228K	–	1383
2021 Q3	$228K	Buy	4,563 +580	+15%	+$35.1K	0.01%	1187
2021 Q2	$251K	Sell	3,983 -5,606	-58%	-$360K	0.01%	1153
2021 Q1	$891K	Buy	9,589 +4,197	+78%	+$430K	0.05%	547
2020 Q4	$483K	Buy	5,392 +3,163	+142%	+$290K	0.04%	668
2020 Q3	$230K	Buy	+2,229	New	+$240K	0.03%	989
2020 Q2	–	Sell	-7,535	Closed	-$436K	–	957
2020 Q1	$436K	Buy	+7,535	New	+$434K	0.05%	629

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaCrest Capital Management's EBS Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 33,648 shares — an estimated $706K sold.

AlphaCrest Capital Management first reported a position in EBS in Q1 2020 and held it in 9 quarters. The position peaked at $1.47M in Q1 2022. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

AlphaCrest Capital Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 33,648 Emergent Biosolutions shares in Q4 2022, an estimated $706K.
AlphaCrest Capital Management first reported a position in Emergent Biosolutions in Q1 2020 and held it in 9 quarters.
AlphaCrest Capital Management's Emergent Biosolutions position peaked at $1.47M in Q1 2022.
198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.